Accesswire · 21 Oct 2026positive
Valion Bio said Interim CEO Dean Zikria’s first-30-day review set priorities to advance Entolimod and other pipeline assets, develop customer and revenue capabilities for its wholly owned Velocity Bioworks CDMO, and evaluate partnerships, co-investment, licensing, or other transactions involving Velocity.
Why it matters — The agenda outlines management’s stated near-term focus across clinical pipeline development and potential ways to build or realize value from Velocity.
Accesswire · 15 Oct 2026positive
Valion Bio and LarmorBio announced that Valion’s wholly owned subsidiary, Velocity Bioworks, completed an initial feasibility evaluation of LarmorBio’s BioScan-NMR platform. The evaluation generated data supporting continued development of real-time, non-invasive bioprocess monitoring for cell size, density, viability, and phenotype.
Why it matters — The milestone marks early progress in developing BioScan-NMR as a process analytical technology for biologics manufacturing, less than six months after Valion secured exclusive rights to the technology.
Accesswire · 14 Oct 2026positive
Valion Bio highlighted capabilities at its wholly owned Velocity Bioworks facility in San Antonio, including process development, analytical services, and early-phase clinical drug substance manufacturing for companies evaluating U.S.-based production. Velocity also supports Valion’s development strategy for Entolimod, its potential medical countermeasure for Acute Radiation Syndrome.
Why it matters — The facility’s services and role in Valion’s domestic biologics supply chain are relevant to watchers assessing the company’s manufacturing capabilities and support for Entolimod development.
Accesswire · 9 Oct 2026positive
Valion Bio said it is developing an oral mucosal formulation of Entolimod that could offer needle-free administration for acute radiation syndrome. The company cited growing electricity demand from AI and data centers, and potential nuclear-power expansion, as reasons to emphasize scalable civilian radiation preparedness.
Why it matters — VBIO watchers may note the company’s potential needle-free delivery approach as it develops a medical countermeasure for radiological or nuclear emergencies.
Accesswire · 5 Oct 2026positive
Valion Bio introduced its new Board Chair, Thomas H. Jensen, who shared his perspectives on advancing the company's lead candidate Entolimod. Jensen previously led Nasdaq-listed Allarity Therapeutics through a refocusing around a single lead asset and noted Valion's combination of government funding, FDA designations, human safety data, and wholly owned U.S. manufacturing.
Why it matters — Valion watchers would care because Jensen's stated biotech turnaround experience may inform how the company advances Entolimod, and his focus on Valion's government funding and regulatory designations highlights potential strengths in its development approach.
